Dehydration and the kidney warning on Foundayo™

What the trials recorded

Section 6.1 gives acute kidney injury as a single pooled figure for Trials 1 and 2 ^[1]. Next to it, it helps to see the three stomach reactions that the label names as the usual route to dehydration, all taken from Table 1 for the highest dose.

Europe’s committee issued a positive opinion in October 2026, but there is no EMA product information yet, so there is no European kidney wording to compare; Health Canada has no Foundayo™ entry ^[3][4].

Rare injury, common triggers

The contrast in that table is the point of the warning. Kidney injury was uncommon, about two people in a thousand on the tablet. The reactions that can lead to it were very common: a quarter or more of people on the top dose reported nausea, diarrhea or vomiting ^[1]. Section 5.4 says most reported cases occurred in people whose stomach reactions led to dehydration.

The label asks prescribers to monitor kidney function in people reporting reactions that could cause fluid loss, especially when treatment starts and when the dose goes up ^[1]. Those are also the periods when, according to section 6.1, nausea, vomiting and diarrhea were most frequent, and the ATTAIN-2 publication likewise reports stomach and bowel events mainly during dose escalation ^[8]. The label’s slow schedule, starting at 0.8 mg with steps at least 30 days apart, is meant to reduce those reactions, and after seven or more missed doses in a row it restarts escalation at a lower dose for the same reason (sections 2.1 and 2.3) ^[1].

Serious kidney cases in the registries

ClinicalTrials.gov lists every serious adverse event whatever its frequency, so the registries show how many kidney problems were classed as serious. The ATTAIN trials used doses of 6, 12 and 36 mg, which the label presents as Foundayo™ 5.5, 9 and 17.2 mg ^[1]. Groups held a few hundred people each, and one or two cases cannot show a difference between treatments ^[5][6][7].

Reading the serious cases

• Serious kidney injury on orforglipron came down to three people across these three trials, and comparison arms had serious kidney events too ^[5][6][7].
• The ATTAIN-2 cases sat in the 12 mg arm, not the highest dose, which is one more reason not to read a dose pattern into single cases ^[6].
• The label’s pooled figure of 0.2% against 0.05% does not separate serious from milder cases ^[1].
• ACHIEVE-3 was open label and in type 2 diabetes, which the US Foundayo™ label does not cover ^[1][7].

Kidney disease and the dose

Section 8.7 recommends no dose change for people with kidney impairment ^[1]. In studies of people with severe kidney impairment and end-stage kidney disease, orforglipron levels did not change, and section 12.3 adds that kidney function across a wide range (eGFR 27.8 to 156 mL/min/1.73 m²) had no clinically relevant effect on how the body handles the medicine ^[1].

There is a reason for that: after a single dose, 87% was recovered in the feces and less than 1% in urine ^[1]. The kidneys play almost no part in clearing orforglipron. The dedicated kidney study measured drug levels after a single 0.8 mg dose, so it describes how the body handles orforglipron rather than longer-term outcomes in advanced kidney disease ^[1].

Reports after approval

Section 6.2 lists acute renal failure and worsening of chronic renal failure, sometimes requiring hemodialysis, among reports collected for GLP-1 receptor agonists as a class after approval ^[1]. These voluntary reports have no reliable frequency and are not specific to Foundayo™, but they explain why the label treats fluid loss seriously.

How fluid loss can reach the kidneys

• From the label: most reported cases followed stomach reactions that led to dehydration, and the warning itself is titled acute kidney injury due to volume depletion ^[1].
• Plausible but not measured: MedlinePlus explains that very low blood pressure, which dehydration can cause, reduces blood flow to the kidneys ^[9], and the label reports low blood pressure in 2% on Foundayo™ against 0.5% on placebo ^[1]. Whether low blood pressure played a part in any trial case is not reported.
• General background: MedlinePlus defines acute kidney failure as a rapid loss, within less than two days, of the kidneys’ ability to remove waste and balance fluids and electrolytes ^[9]. It also notes that older adults and people with diabetes are at higher risk of dehydration ^[10].

Other causes of sudden kidney injury

MedlinePlus lists many causes besides dehydration ^[9]:

• Medicines, including non-steroidal anti-inflammatory drugs (NSAIDs), certain antibiotics and blood pressure medicines, intravenous contrast dye and some cancer and HIV medicines.
• Infections that injure the kidney directly, such as acute pyelonephritis, or septicaemia.
• Blood clots or cholesterol emboli in the kidney’s blood vessels, and autoimmune kidney disease.
• Very low blood pressure from burns, bleeding, injury, septic shock, serious illness or surgery.
• A blocked urinary tract, pregnancy complications and illicit drugs such as cocaine and heroin.

Fluids and kidney tests in plain terms

The Medication Guide stresses drinking enough to reduce the risk of dehydration and asks for a prompt call to your provider when nausea, vomiting or diarrhea will not settle ^[2]. Section 17 adds that your prescriber should explain the signs of acute kidney injury to you ^[1].

For someone losing fluids, MedlinePlus suggests sipping water or sucking ice cubes, drinking water or sports drinks with electrolytes and not taking salt tablets. It says anyone with fever, vomiting or diarrhea should drink plenty without waiting for signs of dehydration, and that carers should watch how much an ill family member manages to drink ^[10].

Kidney function is checked with blood and urine tests. NIDDK describes a blood test for glomerular filtration rate (GFR), estimated from creatinine, and a urine test for albumin, and advises testing for people with diabetes, high blood pressure, heart disease or a family history of kidney failure ^[11]. MedlinePlus adds blood urea nitrogen, potassium and other electrolytes and a urinalysis when sudden kidney failure is suspected ^[9].

What section 17 asks of patients

• Take precautions to avoid fluid depletion while on the tablet ^[1].
• Learn the signs and symptoms of acute kidney injury from your prescriber ^[1].
• Report promptly any nausea, vomiting or diarrhea that is persistent or prolonged, and any signs of kidney injury ^[1].
• Tell every provider about all the medicines you take, including over-the-counter products and supplements ^[2].

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help